Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85.
AuthorsMalin, Adam S
Smith, Steven M
Dockrell, Hazel M
AffiliationImmunology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, WC1E 7HT, London, UK. email@example.com
MetadataShow full item record
AbstractThere is increasing evidence to implicate a role for CD8(+) T cells in protective immunity against tuberculosis. Recombinant vaccinia (rVV) expressing Mycobacterium tuberculosis (MTB) proteins can be used both as tools to dissect CD8(+) T-cell responses and, in attenuated form, as candidate vaccines capable of inducing a balanced CD4(+)/CD8(+) T-cell response. A panel of rVV was constructed to express four immunodominant secreted proteins of MTB: 85A, 85B and 85C and ESAT-6. A parallel group of rVV was constructed to include the heterologous eukaryotic tissue plasminogen activator (tPA) signal sequence to assess if this would enhance expression and immunogenicity. Clear expression was obtained for 85A, 85B and ESAT-6 and the addition of tPA resulted in N-glycosylation and a 4-10-fold increase in expression. Female C57BL/6 mice were immunised using the rVV-Ag85 constructs, and interleukin-2 and gamma-interferon were assayed using a co-culture of immune splenocytes and recall antigen. There was a marked increase in cytokine production in mice immunised with the tPA-containing constructs. We report the first data demonstrating enhanced immunogenicity of rVV using a tPA signal sequence, which has significant implications for future vaccine design.
CitationVaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85. 2000, 2 (14):1677-85 Microbes Infect.
JournalMicrobes and Infection
- Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis.
- Authors: Kou Y, Xu Y, Zhao Z, Liu J, Wu Y, You Q, Wang L, Gao F, Cai L, Jiang C
- Issue date: 2017 Oct
- Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
- Authors: Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV
- Issue date: 2003 Aug 1
- Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice.
- Authors: Xu Y, Zhu B, Wang Q, Chen J, Qie Y, Wang J, Wang H, Wang B, Wang H
- Issue date: 2007 Dec
- Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
- Authors: Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL
- Issue date: 2010 May
- Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences.
- Authors: Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S
- Issue date: 1999 Sep